Proteomic Biomarker Panel for Gauging Multiple Sclerosis Disease Activity: A Case Series From Real-World Use.

Q1 Nursing

International journal of MS care Pub Date : 2025-03-24 eCollection Date: 2025-01-01 DOI:10.7224/1537-2073.2024-094

Taylor Gonyou, Patricia Izbicki, Jim Eubanks, Ferhan Qureshi, William Boudouris, Martin Belkin, Sonda Rossman, Yang Mao-Draayer

{"title":"Proteomic Biomarker Panel for Gauging Multiple Sclerosis Disease Activity: A Case Series From Real-World Use.","authors":"Taylor Gonyou, Patricia Izbicki, Jim Eubanks, Ferhan Qureshi, William Boudouris, Martin Belkin, Sonda Rossman, Yang Mao-Draayer","doi":"10.7224/1537-2073.2024-094","DOIUrl":null,"url":null,"abstract":"Background: Advances in serum proteomics have provided more precise tools for the characterization of multiple sclerosis (MS) and enabled enhanced clinical management of the disease. The multivariate proteomic Multiple Sclerosis Disease Activity (MSDA) test has been analytically and clinically validated.Methods: This is a single-center retrospective case series. Four women with MS were monitored between 2022 and 2023 with up to 2 MSDA time points. Their full clinical histories and exams, along with treatment and MRI changes, were collected with the MSDA tests.Results: Patients' baseline and follow-up MSDA scores were consistent with disease activity, treatment response, and disease stability.Conclusions: We provide a real-world case series to show that MSDA could help to determine MS disease activity at baseline and throughout the disease course. MSDA could help to differentiate clinically stable vs active patients to monitor DMT treatment response.","PeriodicalId":14150,"journal":{"name":"International journal of MS care","volume":"27 Q1","pages":"90-94"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11933741/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of MS care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7224/1537-2073.2024-094","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Nursing","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Advances in serum proteomics have provided more precise tools for the characterization of multiple sclerosis (MS) and enabled enhanced clinical management of the disease. The multivariate proteomic Multiple Sclerosis Disease Activity (MSDA) test has been analytically and clinically validated.

Methods: This is a single-center retrospective case series. Four women with MS were monitored between 2022 and 2023 with up to 2 MSDA time points. Their full clinical histories and exams, along with treatment and MRI changes, were collected with the MSDA tests.

Results: Patients' baseline and follow-up MSDA scores were consistent with disease activity, treatment response, and disease stability.

Conclusions: We provide a real-world case series to show that MSDA could help to determine MS disease activity at baseline and throughout the disease course. MSDA could help to differentiate clinically stable vs active patients to monitor DMT treatment response.

查看原文本刊更多论文

用于测量多发性硬化症活动的蛋白质组学生物标志物面板：来自现实世界使用的病例系列。

背景：血清蛋白质组学的进展为多发性硬化症（MS）的表征提供了更精确的工具，并增强了该疾病的临床管理。多变量蛋白质组学多发性硬化症活动性（MSDA）测试已被分析和临床验证。方法：这是一个单中心回顾性病例系列。在2022年至2023年期间，对4名多发性硬化症女性进行了最多2个MSDA时间点的监测。他们的全部临床病史和检查，以及治疗和MRI变化，与MSDA测试一起收集。结果：患者的基线和随访MSDA评分与疾病活动性、治疗反应和疾病稳定性一致。结论：我们提供了一个真实世界的病例系列，表明MSDA可以帮助确定MS疾病在基线和整个病程中的活动性。MSDA可以帮助区分临床稳定和活跃的患者，以监测DMT治疗反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International journal of MS care Nursing-Advanced and Specialized Nursing

CiteScore

3.00

自引率

0.00%

发文量